# A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

> **NCT02648438** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** AZD7594 Solution for infusion (150 μg intravenous formulation)
- **DRUG:** AZD7594 Oral suspension (1200 μg oral formulation)
- **DRUG:** AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
- **DRUG:** AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
- **DRUG:** AZD7594 Pressurized inhalation suspension (400 μg) by pMDI

## Key facts

- **NCT ID:** NCT02648438
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-12
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-06-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02648438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02648438, "A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02648438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*